Difference between revisions of "Flumatinib (Xinfu)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "clinicaltrials.gov/ct2/show" to "clinicaltrials.gov/study") |
Warner-admin (talk | contribs) m (Text replacement - "(NCT[0-9]{8}) Clinical Trial Registry" to "$1 $1") |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 2: | Line 2: | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/flumatinib-mesylate NCI Drug Dictionary]: The orally bioavailable, mesylate salt form of the tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity. Upon administration, flumatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the proliferation of tumor cells in which these kinases are overexpressed. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/flumatinib-mesylate NCI Drug Dictionary]: The orally bioavailable, mesylate salt form of the tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity. Upon administration, flumatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the proliferation of tumor cells in which these kinases are overexpressed. | ||
| − | == | + | ==Diseases for which it is used== |
| − | + | *[[Chronic myeloid leukemia]] | |
| − | + | # '''FESTnd:''' Zhang L, Meng L, Liu B, Zhang Y, Zhu H, Cui J, Sun A, Hu Y, Jin J, Jiang H, Zhang X, Li Y, Liu L, Zhang W, Liu X, Gu J, Qiao J, Ouyang G, Liu X, Luo J, Jiang M, Xie X, Li J, Zhao C, Zhang M, Yang T, Wang J. Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study. Clin Cancer Res. 2021 Jan 1;27(1):70-77. Epub 2020 Sep 14. [https://doi.org/10.1158/1078-0432.ccr-20-1600 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32928796/ PubMed] [https://clinicaltrials.gov/study/NCT02204644 NCT02204644] | |
| + | ==History of changes in NMPA approval== | ||
| + | *2019-11-25: Initial approval for the treatment of adult patients with Philadelphia chromosome positive [[Chronic myeloid leukemia|chronic myelogenous leukemia]] (Ph＋CML) in the chronic phase. | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' HH-GV-678 | *'''Code name:''' HH-GV-678 | ||
*'''Generic name:''' flumatinib mesylate | *'''Generic name:''' flumatinib mesylate | ||
| + | *'''Brand name:''' Xinfu | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 17: | Line 20: | ||
[[Category:PDGFR inhibitors]] | [[Category:PDGFR inhibitors]] | ||
| − | [[Category:Chronic myeloid leukemia medications | + | [[Category:Chronic myeloid leukemia medications]] |
| − | [[Category: | + | [[Category:NMPA approved in 2019]] |
Latest revision as of 11:58, 4 July 2023
General information
From the NCI Drug Dictionary: The orally bioavailable, mesylate salt form of the tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity. Upon administration, flumatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the proliferation of tumor cells in which these kinases are overexpressed.
Diseases for which it is used
- FESTnd: Zhang L, Meng L, Liu B, Zhang Y, Zhu H, Cui J, Sun A, Hu Y, Jin J, Jiang H, Zhang X, Li Y, Liu L, Zhang W, Liu X, Gu J, Qiao J, Ouyang G, Liu X, Luo J, Jiang M, Xie X, Li J, Zhao C, Zhang M, Yang T, Wang J. Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study. Clin Cancer Res. 2021 Jan 1;27(1):70-77. Epub 2020 Sep 14. link to original article PubMed NCT02204644
History of changes in NMPA approval
- 2019-11-25: Initial approval for the treatment of adult patients with Philadelphia chromosome positive chronic myelogenous leukemia (Ph＋CML) in the chronic phase.
Also known as
- Code name: HH-GV-678
- Generic name: flumatinib mesylate
- Brand name: Xinfu